Anney Lin

FDA investigator

Appears on 9 documents from 2023 to 2026, mostly at sites in California. Most often cites testing and approval or rejection of components, drug product containers, and closures (21 CFR 211.84).

9
Documents on file
5.1
Observations per 483
2023
First seen
2026
Most recent

What they cite most

From 46 observations

Activity by year

2023: 2, 2024: 1, 2025: 4, 2026: 2

Where

California 7 · Oregon 1 · Washington 1

Is Anney Lin coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

9 documents, newest first
FirmOpen
483 Jubilant HollisterStier LLCJun 17, 2026 · Spokane, Washington
483 Element Materials Technology OaklandJan 30, 2026 · Concord, California
483 HTO Nevada Inc. dba KirkmanAug 22, 2025 · Lake Oswego, Oregon
483 Columbia Cosmetics Manufacturing, Inc.Apr 14, 2025 · San Leandro, California
483 Libby Laboratories, IncMar 14, 2025 · Berkeley, California
483 DLC Laboratories, Inc.Jan 31, 2025 · Paramount, California
483 Polypeptide Laboratories IncMay 10, 2024 · Torrance, California

About this profile

What does Anney Lin inspect?

Anney Lin appears on 9 documents on file covering 9 sites, mostly in California.

What do they cite most often?

21 CFR 211.84 (testing and approval or rejection of components, drug product containers, and closures), followed by 21 CFR 211.192 and 21 CFR 211.22(a).

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Anney Lin is dated Jun 17, 2026.